A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Purpose
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Condition
- Nonalcoholic Steatohepatitis
Eligibility
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
- Participants must have a body mass index (BMI) ≥27 kilograms per square meter (kg/m²)
and ≤50 kg/m² with stable body weight for at least 3 months
- Participants with or without type 2 diabetes mellitus (T2DM)
- If with T2DM, hemoglobin A1c (HbA1c) ≤9.5%
- Participants must be willing to undergo baseline and endpoint liver biopsies
- Participants must have histologic diagnosis of NASH with stage 2 or 3 fibrosis by
liver biopsy
- Participants must not have known or suspected alcohol abuse (>14 units/week for women
and >21 units/week for men) or active substance abuse
- Participants must not have evidence of cirrhosis or other forms of liver disease
- Participants must not have heart attack, stroke, or hospitalization for congestive
heart failure in the past 6 months
- Participants must not have active cancer within the last 5 years
- Participants must not have uncontrolled high blood pressure
- Participants must not have renal impairment with estimated glomerular filtration rate
(eGFR) <30 milliters/minute/1.73m²; for participants on metformin, eGFR <45
mL/min/1.73m²
- Participants must not have a diagnosis of type 1 diabetes
- Participants must not have a history of pancreatitis (acute or chronic)
- Participants must not have calcitonin ≥35 nanograms per liter
- Participant must not have family or personal history of multiple endocrine neoplasia
type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
- Female participants must not be pregnant, breast-feeding, or intend to become pregnant
or of childbearing potential and not using adequate contraceptive method (adequate
contraceptive measures as required by local regulation or practice)
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental 5 mg Tirzepatide |
5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week. |
|
Experimental 10 mg Tirzepatide |
10 mg tirzepatide administered SC once a week. |
|
Experimental 15 mg Tirzepatide |
15 mg tirzepatide administered SC once a week. |
|
Placebo Comparator Placebo |
Placebo administered SC once a week. |
|
More Details
- Status
- Active, not recruiting
- Sponsor
- Eli Lilly and Company